Voyager Therapeutics, Inc. (NASDAQ:VYGR) Given Average Recommendation of “Buy” by Brokerages

Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGRGet Rating) have earned a consensus recommendation of “Buy” from the seven brokerages that are covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $15.00.

A number of analysts have recently commented on VYGR shares. StockNews.com cut Voyager Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, April 30th. Zacks Investment Research cut Voyager Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday. Finally, Chardan Capital boosted their price target on Voyager Therapeutics from $4.00 to $6.00 in a research report on Wednesday, March 9th.

NASDAQ:VYGR traded up $0.79 during midday trading on Tuesday, reaching $6.06. The company had a trading volume of 31,028 shares, compared to its average volume of 721,672. The stock’s fifty day simple moving average is $7.53 and its 200-day simple moving average is $4.72. Voyager Therapeutics has a 12-month low of $2.46 and a 12-month high of $10.60. The firm has a market capitalization of $232.72 million, a price-to-earnings ratio of -3.23 and a beta of 1.08.

Voyager Therapeutics (NASDAQ:VYGRGet Rating) last posted its earnings results on Wednesday, May 4th. The company reported ($0.56) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.19). Voyager Therapeutics had a negative return on equity of 76.83% and a negative net margin of 224.48%. As a group, equities research analysts predict that Voyager Therapeutics will post -1.65 earnings per share for the current fiscal year.

In other Voyager Therapeutics news, COO Robin Swartz sold 4,413 shares of the business’s stock in a transaction on Monday, March 21st. The stock was sold at an average price of $8.29, for a total value of $36,583.77. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Robert W. Hesslein sold 4,955 shares of the business’s stock in a transaction on Monday, March 21st. The shares were sold at an average price of $8.29, for a total value of $41,076.95. The disclosure for this sale can be found here. Insiders sold a total of 16,933 shares of company stock worth $124,170 in the last 90 days. 25.40% of the stock is currently owned by insiders.

A number of large investors have recently bought and sold shares of the business. Belvedere Trading LLC boosted its position in Voyager Therapeutics by 4.9% in the 1st quarter. Belvedere Trading LLC now owns 36,340 shares of the company’s stock valued at $347,000 after buying an additional 1,683 shares during the last quarter. Virtu Financial LLC acquired a new stake in Voyager Therapeutics during the fourth quarter worth about $28,000. Marshall Wace LLP acquired a new stake in Voyager Therapeutics during the fourth quarter worth about $1,195,000. Millennium Management LLC raised its stake in Voyager Therapeutics by 54.8% during the fourth quarter. Millennium Management LLC now owns 423,058 shares of the company’s stock worth $1,146,000 after acquiring an additional 149,698 shares during the period. Finally, Cubist Systematic Strategies LLC acquired a new stake in Voyager Therapeutics during the fourth quarter worth about $56,000. 46.16% of the stock is owned by institutional investors.

About Voyager Therapeutics (Get Rating)

Voyager Therapeutics, Inc, a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy.

Recommended Stories

Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.